Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2014 by Medicine, National University Hospital, Singapore.
Recruitment status was:  Recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Medicine, National University Hospital, Singapore Identifier:
First received: July 28, 2010
Last updated: April 1, 2014
Last verified: April 2014

The aim of this study is to determine the outcomes when using ertapenem for complicated urinary tract infections in the OPAt setting.

The study hypothesis: Ertapenem is an efficacious and safe therapeutic option for complicated urinary tract infections in the OPAt setting.

Condition Intervention
Urinary Tract Infections
Drug: Ertapenem

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Prospective Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.

Resource links provided by NLM:

Further study details as provided by Medicine, National University Hospital, Singapore:

Primary Outcome Measures:
  • Clinical Outcome [ Time Frame: within 14 days of treatment and within 1 months after the treatment completion. ]

    Measured by:

    1. Clinical features within 14 days of treatmnet:(improving/resolving/deteriorating) during therapy in OPAT eg dysuria,suprapubic pain, frequency, fever, urinalysis.
    2. Clinical features of recurrences with 1 month after therapy completion
    3. Presence of hospitalization and/or
    4. Mortality

Secondary Outcome Measures:
  • Microbiology outcome [ Time Frame: 30 days after completion of treatment ]

    Measured by:

    urine culture results at the end of treatment and 30 days subsequent

Estimated Enrollment: 60
Study Start Date: August 2010
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Ertapenem
    Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
    Other Name: Invanz
Detailed Description:

Enterobactericae spp. is a common cause of urinary tract infections. The prevalence of quinolone-resistance in Enterobactericae is rising and often co-exists with expression of extended-spectrum beta-lactamases (ESBL, limiting viable outpatient therapeutics options.

In Singapore, there is an increasing trend of treating patients who respond favourably to initial antimicrobial therapy in the outpatient setting (Fisher,, 2006). Ertapenem is one of several agents with excellent antimicrobial activity against Enterobactericae (including ESBL producers). In view of its safety profile and its viability in elastromeric pump, it has great potential to be used in OPAT patients.

There is no study analyzing outcomes in a large cohort of patients with complicated urinary tract infections treated with ertapenem.


Ages Eligible for Study:   21 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults OPAT patients diagnosed with complicated urinary tract infections and whom require IV Ertapenem will be enrolled over a period of 1-2 years.

Inclusion Criteria:

  • Adult patients between 21 years old to 70 years old.
  • Diagnosed with complicated urinary tract infection due to pathogen susceptible to ertapenem based on microbiology report, and the use of ertapenem is deemed clinically appropriate by the Infectious Disease physician in charge.

Exclusion Criteria:

  • Hypersensitivity reactions to Ertapenem.
  • Participation in another interventional clinical investigation within 30days
  • Unable to obtain informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01173068

Contact: Dale A Fisher (65) 6772 43 73
Contact: Zuraidah Bt Sulaiman (65) 6772 2083

National University Hospital Recruiting
Singapore, Singapore, 119074
Sub-Investigator: Zuraidah Sulaiman         
Sponsors and Collaborators
National University Hospital, Singapore
Merck Sharp & Dohme Corp.
Principal Investigator: Dale A Fisher National University Hospital, Singapore
  More Information

Responsible Party: Medicine, A/Prof Dale Fisher, National University Hospital, Singapore Identifier: NCT01173068     History of Changes
Other Study ID Numbers: DSRB Domain E/10/312
Study First Received: July 28, 2010
Last Updated: April 1, 2014

Keywords provided by Medicine, National University Hospital, Singapore:
Clinical outcome
Complicated Urinary Tract Infections

Additional relevant MeSH terms:
Communicable Diseases
Urinary Tract Infections
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 25, 2017